Joe is a highly experienced oncology and cardiovascular drug development leader with over 20 years of experience spanning early discovery to late clinical development. Over his career, Joe has played a critical role in the development of 6 major approved drugs including SYLVANT®, RYBREVANT®, TECVAYLI®, TALVEY®, TAFINLAR® and MEKINIST®. In his prior role as Vice President, Global Head of Oncology Discovery and External Innovation at Johnson & Johnson (J&J), Joe delivered multiple positive proof-of-concept medicines while also driving a strategy of external innovation that resulted in over 50 licensing deals to access critical innovative technologies and assets.

He built a team approach to open innovation that was industry leading. Under Joe’s leadership, J&J discovery and clinical pipelines advanced a significant number of internal and external candidates across diverse modalities, including T cell redirection, T cell co-stimulation, ADCs, and targeted radiotherapy. His contributions have been instrumental in shaping innovative therapeutic strategies and delivering transformational oncology medicines to patients.

Prior to J&J, Joe was both clinical project leader and head of Cancer Research Strategy and Operations at GlaxoSmithKline (GSK), where he drove the approval of a combination novel-novel regimen, TAFINLAR® and MEKINIST®, with an innovative approach across early and late drug development. Joe earned his PhD in pharmacology at the University of Pennsylvania and completed his postdoctoral research at GSK.